Ribociclib/fulvestrant combination generates PFS improvement in metastatic breast cancer.- Novartis
Ribociclib (Kisqali) plus switch endocrine therapy induced a statistically significant progression-free survival (PFS) benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor (HR)–positive, HER2-negative, metastatic breast cancer, according to findings from the phase II MAINTAIN trial (NCT02632045) previously presented at the 2022 ASCO Annual Meeting, now published in the Journal of Clinical Oncology